Copyright © 2008 Guido Eibl. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar
2. K. K. Kazanjian, O. J. Hines, J. P. Duffy, et al., “Improved survival for adenocarcinoma of the pancreas after pancreaticoduodenectomy,” Gastroenterology, vol. 128, pp. A813–A814, 2005.
3. S. Boeck, D. P. Ankerst, and V. Heinemann, “The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis,” Oncology, vol. 72, no. 5-6, pp. 314–321, 2008. View at Publisher · View at Google Scholar · View at PubMed
4. S. Shore, M. G. T. Raraty, P. Ghaneh, and J. P. Neoptolemos, “Review article: chemotherapy for pancreatic cancer,” Alimentary Pharmacology & Therapeutics, vol. 18, no. 11-12, pp. 1049–1069, 2003. View at Publisher · View at Google Scholar
5. M. J. Moore, D. Goldstein, J. Hamm, et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at PubMed
6. A. B. Lowenfels and P. Maisonneuve, “Epidemiology and risk factors for pancreatic cancer,” Best Practice and Research in Clinical Gastroenterology, vol. 20, no. 2, pp. 197–209, 2006. View at Publisher · View at Google Scholar · View at PubMed
7. E. Giovannucci and D. Michaud, “The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas,” Gastroenterology, vol. 132, no. 6, pp. 2208–2225, 2007. View at Publisher · View at Google Scholar · View at PubMed
8. A. Russo, M. Autelitano, and L. Bisanti, “Metabolic syndrome and cancer risk,” European Journal of Cancer, vol. 44, no. 2, pp. 293–297, 2008. View at Publisher · View at Google Scholar · View at PubMed
9. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
10. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Publisher · View at Google Scholar · View at PubMed
11. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at PubMed
12. R. Pakala, P. Kuchulakanti, S.-W. Rha, E. Cheneau, R. Baffour, and R. Waksman, “Peroxisome proliferator-activated receptor $\gamma$: its role in metabolic syndrome,” Cardiovascular Radiation Medicine, vol. 5, no. 2, pp. 97–103, 2004. View at Publisher · View at Google Scholar · View at PubMed
13. R. K. Semple, V. K. K. Chatterjee, and S. O'Rahilly, “PPAR$\gamma$ and human metabolic disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006. View at Publisher · View at Google Scholar · View at PubMed
14. C. E. Quinn, P. K. Hamilton, C. J. Lockhart, and G. E. McVeigh, “Thiazolidinediones: effects on insulin resistance and the cardiovascular system,” British Journal of Pharmacology, vol. 153, no. 4, pp. 636–645, 2008. View at Publisher · View at Google Scholar · View at PubMed
15. A. Kepez, A. Oto, and S. Dagdelen, “Peroxisome proliferator-activated receptor-$\gamma$: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis,” BioDrugs, vol. 20, no. 2, pp. 121–135, 2006. View at Publisher · View at Google Scholar
16. A. Pfützner, C. A. Schneider, and T. Forst, “Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects,” Expert Review of Cardiovascular Therapy, vol. 4, no. 4, pp. 445–459, 2006. View at Publisher · View at Google Scholar · View at PubMed
17. D. Walcher and N. Marx, “Insulin resistance and cardiovascular disease: the role of PPAR$\gamma$ activators beyond their anti-diabetic action,” Diabetes & Vascular Disease Research, vol. 1, no. 2, pp. 76–81, 2004.
18. S. Han and J. Roman, “Peroxisome proliferator-activated receptor $\gamma$: a novel target for cancer therapeutics?,” Anti-Cancer Drugs, vol. 18, no. 3, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at PubMed
19. A. Krishnan, S. A. Nair, and M. R. Pillai, “Biology of PPAR$\gamma$ in cancer: a critical review on existing lacunae,” Current Molecular Medicine, vol. 7, no. 6, pp. 532–540, 2007. View at Publisher · View at Google Scholar
20. G. Kristiansen, J. Jacob, A.-C. Buckendahl, et al., “Peroxisome proliferator-activated receptor $\gamma$ is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” Clinical Cancer Research, vol. 12, no. 21, pp. 6444–6451, 2006. View at Publisher · View at Google Scholar · View at PubMed
21. M. Lehrke and M. A. Lazar, “The many faces of PPAR$\gamma$,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at PubMed
22. A. Galli, T. Mello, E. Ceni, E. Surrenti, and C. Surrenti, “The potential of antidiabetic thiazolidinediones for anticancer therapy,” Expert Opinion on Investigational Drugs, vol. 15, no. 9, pp. 1039–1049, 2006. View at Publisher · View at Google Scholar · View at PubMed
23. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor $\gamma$ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar · View at PubMed
24. D. Panigrahy, L. Q. Shen, M. W. Kieran, and A. Kaipainen, “Therapeutic potential of thiazolidinediones as anticancer agents,” Expert Opinion on Investigational Drugs, vol. 12, no. 12, pp. 1925–1937, 2003. View at Publisher · View at Google Scholar · View at PubMed
25. K. Yang, K.-H. Fan, S. A. Lamprecht, et al., “Peroxisome proliferator-activated receptor $\gamma$ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in $Ap{c}^{1638\text{N/+}}$$Mlh{1}^{+/-}$ double mutant mice,” International Journal of Cancer, vol. 116, no. 4, pp. 495–499, 2005. View at Publisher · View at Google Scholar · View at PubMed
26. I. K. Choi, Y. H. Kim, J. S. Kim, and J. H. Seo, “PPAR-$\gamma$ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo,” Investigational New Drugs, vol. 26, no. 3, pp. 283–288, 2008. View at Publisher · View at Google Scholar · View at PubMed
27. E. Saez, J. Rosenfeld, A. Livolsi, et al., “PPAR$\gamma$ signaling exacerbates mammary gland tumor development,” Genes and Development, vol. 18, no. 5, pp. 528–540, 2004. View at Publisher · View at Google Scholar · View at PubMed
28. A.-M. Lefebvre, I. Chen, P. Desreumaux, et al., “Activation of the peroxisome proliferator-activated receptor $\gamma$ promotes the development of colon tumors in C57BL/6J-${\text{APC}}^{Min}$/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998. View at Publisher · View at Google Scholar · View at PubMed
29. M. V. Pino, M. F. Kelley, and Z. Jayyosi, “Promotion of colon tumors in C57BL/6J-${\text{APC}}^{Min}$/+ mice by thiazolidinedione PPAR$\gamma$ agonists and a structurally unrelated PPAR$\gamma$ agonist,” Toxicologic Pathology, vol. 32, no. 1, pp. 58–63, 2004. View at Publisher · View at Google Scholar
30. E. Ceni, T. Mello, M. Tarocchi, et al., “Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells,” World Journal of Gastroenterology, vol. 11, no. 8, pp. 1122–1130, 2005.
31. S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR$\gamma$ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar
32. K. Hashimoto, B. J. Farrow, and B. M. Evers, “Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell Line MIA PaCa-2,” Pancreas, vol. 28, no. 2, pp. 153–159, 2004. View at Publisher · View at Google Scholar
33. A. Galli, E. Ceni, D. W. Crabb, et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR$\gamma$ independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004. View at Publisher · View at Google Scholar · View at PubMed
34. W. Motomura, M. Nagamine, S. Tanno, et al., “Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells,” Journal of Gastroenterology, vol. 39, no. 5, pp. 461–468, 2004. View at Publisher · View at Google Scholar · View at PubMed
35. M. A. K. Rumi, S. Ishihara, H. Kazumori, Y. Kadowaki, and Y. Kinoshita, “Can PRAR$\gamma$ ligands be used in cancer therapy?,” Current Medicinal Chemistry, vol. 4, no. 6, pp. 465–477, 2004. View at Publisher · View at Google Scholar
36. J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M. D. Ringel, and C.-S. Chen, “Beyond peroxisome proliferator-activated receptor $\gamma$ signaling: the multi-facets of the antitumor effect of thiazolidinediones,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 401–413, 2006. View at Publisher · View at Google Scholar · View at PubMed
37. D. L. Feinstein, A. Spagnolo, C. Akar, et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?,” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005. View at Publisher · View at Google Scholar · View at PubMed
38. I. Samudio, M. Konopleva, N. Hail, Jr., et al., “2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer,” Journal of Biological Chemistry, vol. 280, no. 43, pp. 36273–36282, 2005. View at Publisher · View at Google Scholar · View at PubMed
39. M. Abdelrahim, K. Newman, K. Vanderlaag, I. Samudio, and S. Safe, “3,$3^{\prime }$-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5,” Carcinogenesis, vol. 27, no. 4, pp. 717–728, 2006. View at Publisher · View at Google Scholar · View at PubMed
40. G. Eibl, M. N. Wente, H. A. Reber, and O. J. Hines, “Peroxisome proliferator-activated receptor $\gamma$ induces pancreatic cancer cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 522–529, 2001. View at Publisher · View at Google Scholar · View at PubMed
41. H. Sawai, J. Liu, H. A. Reber, O. J. Hines, and G. Eibl, “Activation of peroxisome proliferator-activated receptor-$\gamma$ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system,” Molecular Cancer Research, vol. 4, no. 3, pp. 159–167, 2006. View at Publisher · View at Google Scholar · View at PubMed
42. G. Eibl, Y. Takata, L. G. Boros, et al., “Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor,” Cancer Research, vol. 65, no. 3, pp. 982–990, 2005.
43. A. Margeli, G. Kouraklis, and S. Theocharis, “Peroxisome proliferator activated receptor-$\gamma$ (PPAR-$\gamma$) ligands and angiogenesis,” Angiogenesis, vol. 6, no. 3, pp. 165–169, 2003. View at Publisher · View at Google Scholar · View at PubMed
44. F. Biscetti, E. Gaetani, A. Flex, et al., “Selective activation of peroxisome proliferator-activated receptor (PPAR)$\alpha$ and PPAR$\gamma$ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism,” Diabetes, vol. 57, no. 5, pp. 1394–1404, 2008. View at Publisher · View at Google Scholar · View at PubMed
45. Y. Takeuchi, M. Takahashi, K. Sakano, et al., “Suppression of $N$-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor $\gamma$,” Carcinogenesis, vol. 28, no. 8, pp. 1692–1696, 2007. View at Publisher · View at Google Scholar · View at PubMed
46. W. L. Smith, L. J. Marnett, and D. L. DeWitt, “Prostaglandin and thromboxane biosynthesis,” Pharmacology and Therapeutics, vol. 49, no. 3, pp. 153–179, 1991. View at Publisher · View at Google Scholar
47. M. Negishi, Y. Sugimoto, and A. Ichikawa, “Molecular mechanisms of diverse actions of prostanoid receptors,” Biochimica et Biophysica Acta, vol. 1259, no. 1, pp. 109–120, 1995. View at Publisher · View at Google Scholar
48. M. Negishi and H. Katoh, “Cyclopentenone prostaglandin receptors,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 611–617, 2002. View at Publisher · View at Google Scholar
49. A. G. Spencer, J. W. Woods, T. Arakawa, I. I. Singer, and W. L. Smith, “Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy,” Journal of Biological Chemistry, vol. 273, no. 16, pp. 9886–9893, 1998. View at Publisher · View at Google Scholar
50. G. Eibl, H. A. Reber, O. J. Hines, and V. L. W. Go, “COX and PPAR: possible interactions in pancreatic cancer,” Pancreas, vol. 29, no. 4, pp. 247–253, 2004. View at Publisher · View at Google Scholar
51. S. A. Kliewer, S. S. Sundseth, S. A. Jones, et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors $\alpha$ and $\gamma$,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar
52. S. Glover, T. Bayburt, M. Jonas, E. Chi, and M. H. Gelb, “Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen,” Journal of Biological Chemistry, vol. 270, no. 25, pp. 15359–15367, 1995. View at Publisher · View at Google Scholar
53. H. Kan, Y. Ruan, and K. U. Malik, “Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells,” Molecular Pharmacology, vol. 50, no. 5, pp. 1139–1147, 1996.
54. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors $\alpha$ and $\gamma$ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar
55. H. Funahashi, M. Satake, D. Dawson, et al., “Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor,” Cancer Research, vol. 67, no. 15, pp. 7068–7071, 2007. View at Publisher · View at Google Scholar · View at PubMed